A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis

The purpose of this first-in-human (FIH) study is to assess the safety and tolerability, pharmacokinetics (PK), immunogenicity (IG) and pharmacodynamics (PD) of DCY636. The results are intended to support the further clinical development of DCY636 in future studies.

NCT Number	NCT07604324
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Dermatitis, Atopic
Enrollment	63 participants
Start Date	2026-06-02
Primary Completion	2028-01-27 (estimated)
Study Completion	2028-01-28 (estimated)
Updated on ClinicalTrials.gov	2026-07-20